Literature DB >> 34936708

MR diffusion and dynamic-contrast enhanced imaging to distinguish meningioma, paraganglioma, and schwannoma in the cerebellopontine angle and jugular foramen.

Yoshiaki Ota1, Eric Liao1, Aristides A Capizzano1, Hajime Yokota2, Akira Baba1, Ryo Kurokawa1, Mariko Kurokawa1, Toshio Moritani1, Kengo Yoshii3, Ashok Srinivasan1.   

Abstract

BACKGROUND AND
PURPOSE: Differentiation of meningiomas, paragangliomas, and schwannomas in the cerebellopontine angle and jugular foramen remains challenging when conventional MRI findings are inconclusive. This study aimed to assess the clinical utility of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) findings for tumor type differentiation and to identify the most significant diagnostic parameters.
METHODS: This retrospective study included 57 patients with pathologically confirmed meningiomas, paragangliomas, and schwannomas, diagnosed between January 2018 and August 2021. DWI and DCE-MRI were obtained before surgery. The apparent diffusion coefficient (ADC) and DCE-MRI parameters were calculated. The Kruskal-Wallis H test and post hoc test with Bonferroni correction and receiver operating characteristic curve were used for statistical analysis.
RESULTS: There were 20 meningiomas (6 men; 62.3 ± 17.8 years), 23 paragangliomas (3 men; 51.6 ± 17.0 years), and 14 schwannomas (7 men; 37.7 ± 20.0 years). Vp showed a significant difference in each comparison (p < .001, <.001, and <.001, respectively), Ve showed significant differences both in meningiomas and paragangliomas, and paragangliomas and schwannomas (p < .001 and .017, respectively), and Ktrans showed significant differences both in meningiomas and paragangliomas, and meningiomas and schwannomas (p = .0018 and <.001, respectively), though there was no significant difference in ADC. Vp diagnostic performance values for each pair of tumors were area under the curve of 0.89-1.00, with cutoff values of 0.14-0.27.
CONCLUSION: DCE-MRI can provide promising parameters to differentiate meningiomas, paragangliomas, and schwannomas in the cerebellopontine angle and jugular foramen.
© 2021 American Society of Neuroimaging.

Entities:  

Keywords:  DCE-MRI; DWI; meningiomas; paraganglioma; schwannomas

Mesh:

Substances:

Year:  2021        PMID: 34936708     DOI: 10.1111/jon.12959

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  5 in total

1.  Prediction of Wound Failure in Patients with Head and Neck Cancer Treated with Free Flap Reconstruction: Utility of CT Perfusion and MR Perfusion in the Early Postoperative Period.

Authors:  Y Ota; A G Moore; M E Spector; K Casper; C Stucken; K Malloy; R Lobo; A Baba; A Srinivasan
Journal:  AJNR Am J Neuroradiol       Date:  2022-03-31       Impact factor: 3.825

2.  Differentiation of Skull Base Chondrosarcomas, Chordomas, and Metastases: Utility of DWI and Dynamic Contrast-Enhanced Perfusion MR Imaging.

Authors:  Y Ota; E Liao; A A Capizzano; A Baba; R Kurokawa; M Kurokawa; A Srinivasan
Journal:  AJNR Am J Neuroradiol       Date:  2022-08-11       Impact factor: 4.966

3.  The value of quantitative magnetic resonance imaging signal intensity in distinguishing between spinal meningiomas and schwannomas.

Authors:  Nguyen Duy Hung; Le Thanh Dung; Dang Khanh Huyen; Ngo Quang Duy; Dong-Van He; Nguyen Minh Duc
Journal:  Int J Med Sci       Date:  2022-06-21       Impact factor: 3.642

4.  Apparent Diffusion Coefficient Values and Dynamic Contrast-Enhanced Magnetic Resonance Perfusion are Potential Predictors for Grading Meningiomas.

Authors:  Sri Andreani Utomo; Abdul Hafid Bajamal; Yuyun Yueniwati; Irfan Deny Sanjaya; Dyah Fauziah
Journal:  Int J Med Sci       Date:  2022-07-18       Impact factor: 3.642

5.  Intracranial paragangliomas versus schwannomas: Role of dynamic susceptibility contrast perfusion and diffusion MRI.

Authors:  Yoshiaki Ota; Eric Liao; Aristides A Capizzano; Akira Baba; Ryo Kurokawa; Mariko Kurokawa; Ashok Srinivasan
Journal:  J Neuroimaging       Date:  2022-05-12       Impact factor: 2.324

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.